97480-93-8 Usage
Uses
Used in Pharmaceutical Industry:
1-(4-PHENYLBUTYL)-PIPERAZINE is used as a therapeutic agent for its potential to act as a serotonin receptor agonist or antagonist, which is crucial for the treatment of various central nervous system disorders.
Used in Psychiatric Disorder Treatment:
1-(4-PHENYLBUTYL)-PIPERAZINE is used as a treatment option for psychiatric disorders due to its influence on serotonin receptors, which play a significant role in mood regulation and various cognitive functions.
Used in Enzyme Inhibition:
1-(4-PHENYLBUTYL)-PIPERAZINE is utilized as an enzyme inhibitor, targeting specific enzymes that may be implicated in disease processes, thereby offering a therapeutic approach to controlling or mitigating these conditions.
Used in Chemical Synthesis:
1-(4-PHENYLBUTYL)-PIPERAZINE is used as a precursor or intermediate in the synthesis of other chemical compounds, highlighting its versatility and importance in the development of new pharmaceuticals and other organic substances.
Check Digit Verification of cas no
The CAS Registry Mumber 97480-93-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,4,8 and 0 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 97480-93:
(7*9)+(6*7)+(5*4)+(4*8)+(3*0)+(2*9)+(1*3)=178
178 % 10 = 8
So 97480-93-8 is a valid CAS Registry Number.
InChI:InChI=1/C14H22N2/c1-2-6-14(7-3-1)8-4-5-11-16-12-9-15-10-13-16/h1-3,6-7,15H,4-5,8-13H2
97480-93-8Relevant academic research and scientific papers
Saturated heterocyclic carboxamide derivatives
-
, (2008/06/13)
A saturated heterocyclic carboxamide derivative of the following general formula (I) and salts thereof which have platelet activating factor (PAF) antagonizing activity. STR1
Novel 1-phenylpiperazine and 4-phenylpiperidine derivatives as high-affinity σ ligands
Glennon,Yousif,Ismaiel,El-Ashmawy,Herndon,Fischer,Server,Howie
, p. 3360 - 3365 (2007/10/02)
σ receptors may represent an exciting new approach for the development of novel psychotherapeutic agents. Unfortunately, many of the commonly used σ ligands lack selectivity (e.g., many bind at phencyclidine or dopamine receptors) or suffer from other ser
